10-Q: Alnylam Reports Strong Product Revenue Growth Amidst Rising Losses and Patent Litigation Setbacks

Alnylam Pharmaceuticals announced significant increases in product revenue, driven by AMVUTTRA's expanded indications, but reported a widening net loss and faced adverse rulings in key patent infringement lawsuits.

Summary

• Total revenues increased by 17% to $773.7 million for the three months ended June 30, 2025, compared to $659.8 million in the same period of 2024.
• Net product revenues surged by 64% to $672.2 million for the three months ended June 30, 2025, up from $410.1 million in the prior year, primarily due to AMVUTTRA.
• AMVUTTRA's total net product revenues grew by 114% to $492.0 million for the three months ended June 30, 2025, largely driven by increased patient demand for ATTR-CM in the U.S.
• ONPATTRO's total net product revenues decreased by 32% to $52.5 million for the three months ended June 30, 2025, primarily due to patient switches to AMVUTTRA.
• GIVLAARI and OXLUMO net product revenues increased by 30% and 15% respectively for the three months ended June 30, 2025.
• Net revenues from collaborations significantly decreased by 73% to $61.5 million for the three months ended June 30, 2025, mainly due to one-time revenue recognition in the prior year from Regeneron ($185.0 million) and Roche ($65.0 million).
• Royalty revenue increased by 78% to $39.9 million for the three months ended June 30, 2025, driven by increased global net sales of Leqvio and Qfitlia.
• Total operating costs and expenses increased by 29% to $789.9 million for the three months ended June 30, 2025.
• Cost of goods sold increased by 111% to $142.0 million, representing 21.1% of net product revenues for the three months ended June 30, 2025, due to higher AMVUTTRA sales and associated royalties.
• Research and development expenses rose by 10% to $323.6 million, and selling, general and administrative expenses increased by 30% to $323.3 million for the three months ended June 30, 2025.
• Net loss for the three months ended June 30, 2025, widened to $66.3 million, compared to a net loss of $16.9 million in the same period of 2024.
• Accumulated deficit reached $7.41 billion as of June 30, 2025.
• Cash, cash equivalents, and marketable securities totaled $2.86 billion as of June 30, 2025.

Sentiment

Score: 6

Explanation: The company shows strong commercial momentum with significant product revenue growth, particularly from AMVUTTRA's expanded indications, and a promising pipeline with positive clinical data and Fast Track designation. However, this is offset by a substantial increase in net losses, rising operating expenses, and adverse outcomes in high-profile patent litigation, introducing considerable financial and legal uncertainties.

Positives

• Net product revenues increased significantly by 64% for the quarter and 47% for the six months ended June 30, 2025, demonstrating strong commercial performance.
• AMVUTTRA sales showed exceptional growth, with total net product revenues increasing by 114% for the quarter and 89% for the six months, primarily driven by demand in ATTR amyloidosis with cardiomyopathy in the U.S.
• AMVUTTRA received FDA approval in March 2025 and European Commission approval in June 2025 for the treatment of ATTR amyloidosis with cardiomyopathy, expanding its market opportunity.
• ONPATTRO received regulatory approval from ANVISA for ATTR amyloidosis with cardiomyopathy in February 2025.
• GIVLAARI and OXLUMO continued to show revenue growth, increasing by 30% and 15% respectively for the quarter, reflecting increased patient numbers.
• Royalty revenue more than doubled (101% increase for six months) due to strong global net sales of Leqvio by Novartis and Qfitlia by Sanofi.
• Qfitlia received FDA approval in March 2025 for routine prophylaxis in hemophilia A or B, marking a significant commercial milestone for the collaborator.
• Positive topline results were reported from the KARDIA-2 clinical trial for zilebesiran in hypertension, supporting its development.
• Nucresiran, an investigational RNAi therapeutic for ATTR amyloidosis, demonstrated positive Phase 1 results with sustained serum TTR reductions greater than 90% through at least Day 180.
• Nucresiran received Fast Track Designation from the FDA for the treatment of ATTR amyloidosis with cardiomyopathy, potentially accelerating its development and review.
• Mivelsiran, an investigational RNAi therapeutic for Alzheimer's disease and cerebral amyloid angiopathy, showed robust, durable, dose-dependent reductions of soluble amyloid precursor protein beta (sAPP) in cerebrospinal fluid in Phase 1.
• Received a $30.0 million payment from Vir Biotechnology, Inc. in March 2025 due to an amended collaboration agreement.
• Maintained a strong cash position with $2.86 billion in cash, cash equivalents, and marketable securities as of June 30, 2025.
• Believes current cash, cash equivalents, and marketable securities will be sufficient to satisfy near-term capital and operating needs for at least the next 12 months.
• The company is targeting financial self-sustainability by the end of 2025 as part of its Alnylam P 5 x25 strategy.

Negatives

• Net loss significantly increased by 292% to $66.3 million for the three months ended June 30, 2025, compared to $16.9 million in the prior year period.
• Loss from operations increased by 133% to $16.2 million for the three months ended June 30, 2025, compared to income from operations of $48.6 million in the prior year period.
• Net revenues from collaborations decreased substantially by 73% for the quarter and 54% for the six months ended June 30, 2025, primarily due to the recognition of large one-time payments from Regeneron ($185.0 million) and Roche ($65.0 million) in the comparable prior periods.
• ONPATTRO sales declined by 32% for the quarter and 30% for the six months, largely due to patients switching to AMVUTTRA.
• Cost of goods sold increased disproportionately to net product revenues, rising by 111% for the quarter and 74% for the six months, and as a percentage of net product revenues from 16.4% to 21.1% for the quarter, driven by increased AMVUTTRA sales and associated royalties.
• Research and development expenses and selling, general and administrative expenses continued to increase, reflecting ongoing investment in pipeline and commercial infrastructure.
• Accumulated deficit grew to $7.41 billion as of June 30, 2025, indicating continued historical losses.
• Regeneron opted out of mivelsiran co-development in May 2024, making the company solely responsible for its funding and development, without future funding from Regeneron.
• The U.S. District Court for the District of Delaware affirmed claim construction rulings in the Moderna patent infringement lawsuit in June 2025, effectively leading to a final judgment of non-infringement for the asserted patents.
• The U.S. District Court for the District of Delaware granted Pfizer's motion for summary judgment of non-infringement in the patent infringement lawsuit in July 2025.
• Moderna filed a motion in October 2024 seeking recovery of fees incurred from September 2023 to October 2024 in the patent lawsuit.
• The Board of Regents of the University of Texas System filed a lawsuit in December 2024 alleging infringement of a patent by ONPATTRO, with motions to dismiss/transfer denied in July 2025, indicating ongoing litigation risk.
• The Phase 1 clinical trial of mivelsiran for Alzheimer's Disease remains on partial clinical hold in the U.S. due to non-clinical chronic toxicology findings, though current development plans are not impacted.

Risks

• The marketing and sale of approved products, including AMVUTTRA for ATTR amyloidosis with cardiomyopathy, or any future products, may be unsuccessful or less successful than anticipated.
• The company has a history of losses and may not become and remain profitable, with an accumulated deficit of $7.41 billion as of June 30, 2025.
• Substantial funds will be required to continue research, development, and commercialization activities, and greater funds than estimated may necessitate limiting or scaling back certain activities.
• Inability to maintain existing or enter into new collaborations with other companies could negatively impact business, as the company relies on third parties for capabilities and funding.
• Material amendment, termination, or failure to perform obligations by any collaborator could delay or terminate the development and commercialization of products or product candidates.
• Significant costs are expected to grow manufacturing capabilities, and continued reliance on third parties for manufacturing products and product candidates poses risks of supply disruption.
• Reliance on third parties to conduct clinical trials means their failure to fulfill obligations could adversely affect development plans.
• Inability to attract and retain qualified key management and scientific, development, medical, and commercial staff, consultants, and advisors could adversely affect business plan implementation.
• Difficulty expanding operations successfully from a U.S.and EU-based company into a global company commercializing multiple products in multiple geographies.
• Any product candidate may fail in development or experience significant delays due to negative or inconclusive nonclinical/clinical results, regulatory hurdles, or patient enrollment difficulties.
• Undesirable side effects or unexpected adverse properties of products or product candidates could delay or prevent regulatory approval, limit commercial potential, or result in significant negative consequences post-marketing approval.
• Inability to obtain U.S. or foreign regulatory approval for product candidates could prevent commercialization.
• Approved products are subject to extensive and ongoing regulatory oversight; failure to comply with continuing requirements could lead to limited or withdrawn approvals or other penalties.
• Significant liability may be incurred if enforcement authorities allege or determine engagement in commercial activities with unapproved product candidates or off-label promotion of approved products.
• Even with regulatory approval, the market may not be receptive to product candidates upon commercial introduction due to competition, pricing, or lack of reimbursement.
• Inability to continue developing and scaling global marketing, sales, market access, and distribution capabilities could hinder successful commercialization.
• Patient populations for ATTR amyloidosis, AHP, and PH1 are not precisely established, and smaller actual patient numbers or failure to raise awareness could adversely affect business.
• Products may become subject to unfavorable pricing regulations or healthcare reform initiatives, such as the Inflation Reduction Act or executive orders aimed at lowering drug prices.
• Inability to achieve and maintain coverage and adequate reimbursement from third-party payors for products could severely hinder commercial success.
• Subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations, with potential for criminal liability and other serious consequences for violations.
• Substantial risk of product liability claims, which may not be sufficiently covered by insurance.
• Employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards or insider trading violations.
• Failure to comply with laws regulating environmental protection and health and human safety could adversely affect business.
• Inability to obtain and enforce patent protection for discoveries could harm ability to develop and commercialize product candidates.
• Licensors may not properly or successfully obtain, maintain, or enforce the patents underlying licenses, harming competitive position.
• Other companies or organizations may challenge patent rights or assert patent rights that prevent development and commercialization of products.
• Involvement in intellectual property litigation or other proceedings, including ongoing patent infringement litigation against Pfizer, Inc. and Moderna, Inc., could incur substantial costs and liability.
• Failure to comply with obligations under licenses or related agreements could result in damages or loss of necessary rights.
• The pharmaceutical market is intensely competitive, and inability to compete effectively with existing drugs, new treatment methods, and new technologies could hinder successful commercialization.
• Competition from other companies developing novel drugs and technology platforms using similar or emerging technologies could adversely affect commercialization.
• Stock price has been and may in the future be volatile, leading to potential decline in investment value.
• Insufficient cash flow from business to pay indebtedness, including convertible notes.
• Inability to raise necessary funds to settle cash conversions of convertible notes or repurchase them upon a fundamental change.
• The conditional conversion feature of the convertible notes, if triggered, may adversely affect liquidity.
• Transactions relating to the convertible notes, including hedging activities by option counterparties, may affect the value of common stock.
• Subject to counterparty risk with respect to Capped Calls, potentially leading to adverse tax consequences or dilution if an Option Counterparty defaults.
• The accounting method for convertible debt securities may have a material effect on reported financial results, potentially increasing reported interest expense and reducing net income or increasing net loss.

Future Outlook

The company expects net revenues from collaborations and royalty revenue to increase in 2025 compared to 2024, driven by the Roche Collaboration and continued growth of Leqvio and Qfitlia sales. Cost of goods sold is also anticipated to increase due to higher AMVUTTRA sales and associated royalties, while cost of collaborations and royalties is expected to decrease as collaborators transition to independent material production. Research and development and selling, general and administrative expenses are projected to continue increasing due to ongoing investments in global commercial infrastructure, future product launches, and pipeline advancement. The company aims to achieve financial self-sustainability by the end of 2025 and plans to report KARDIA-3 Phase 2 clinical trial results and initiate a Phase 3 cardiovascular outcomes trial for zilebesiran in the second half of 2025. Additionally, a Phase 3 clinical trial for nucresiran (TRITON-PN) is expected to initiate in late 2025, and a Phase 2 clinical trial for mivelsiran in Alzheimer's disease is planned for the second half of 2025. The company is evaluating the impact of recent accounting pronouncements and tax law changes on future periods.

Management Comments

• The company is committed to advancing its strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics.
• The company aims to deliver transformative medicines across a broad range of disease areas and indications, benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.
• The company intends to achieve the metrics associated with its Alnylam P 5 x25 strategy, including becoming a top-tier biotech company by the end of 2025.
• The company intends to achieve sustainable operating profitability beginning in 2025.
• The company believes its current cash, cash equivalents, and marketable securities as of June 30, 2025, will be sufficient to satisfy near-term capital and operating needs for at least the next 12 months from the filing date.

Industry Context

Alnylam operates in the highly competitive and rapidly evolving biopharmaceutical market, specializing in RNAi therapeutics. The company's focus on rare diseases like ATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1, as well as prevalent diseases like hypertension and Alzheimer's, places it in direct competition with large pharmaceutical and biotechnology companies. The industry is characterized by intense R&D, high regulatory hurdles, and significant pricing and reimbursement pressures from governments and third-party payors, exemplified by the Inflation Reduction Act and various executive orders aimed at drug price control. The company's strategy of leveraging collaborations (e.g., with Novartis, Sanofi, Roche, Regeneron) is a common industry practice to share development costs and expand market reach. The ongoing patent litigation highlights the critical importance of intellectual property in the biotechnology sector, where disputes over foundational technologies are common. The shift towards new delivery technologies and the emergence of competing platforms like antisense drugs further intensify the competitive landscape.

Comparison to Industry Standards

• AMVUTTRA, approved for ATTR amyloidosis with cardiomyopathy, competes with Pfizer's VYNDAQEL/VYNDAMAX and BridgeBio's ATTRUBY. While AMVUTTRA is administered subcutaneously, its competitors are oral pills and have lower list prices, potentially impacting AMVUTTRA's commercial success.
• For hATTR amyloidosis with polyneuropathy, AMVUTTRA and ONPATTRO compete with Ionis's WAINUA (eplontersen) and TEGSEDI (inotersen), and Pfizer's VYNDAQEL/VYNDAMAX. WAINUA is also subcutaneously administered, while VYNDAQEL/VYNDAMAX is oral.
• OXLUMO for PH1 faces competition from Novo Nordisk's RIVFLOZA (nedosiran), which was approved in September 2023 and launched in early 2024. RIVFLOZA is a once-monthly subcutaneous RNAi therapy, offering a similar administration profile.
• Qfitlia, commercialized by Sanofi, represents a new approach to treating hemophilia by lowering antithrombin. Its acceptance will depend on physician and patient adoption compared to existing hemophilia treatments.
• The company's increasing cost of goods sold as a percentage of net product revenues (21.1% in Q2 2025 vs. 16.4% in Q2 2024) suggests a higher royalty burden or manufacturing costs compared to the prior year, which could impact gross margins relative to industry peers.

Legal Proceedings

• Patent infringement lawsuits filed in March 2022 against Moderna, Inc. and Pfizer, Inc./BioNTech SE regarding their mRNA COVID-19 vaccines. The District Court's claim construction rulings in the Moderna lawsuit led to a final judgment of non-infringement for the asserted patents, affirmed by the Federal Circuit in June 2025. Moderna is seeking recovery of fees.
• In the Pfizer lawsuit, the District Court issued an order in April 2025 effectively placing the Pfizer product outside patent coverage, and granted Pfizer's motion for summary judgment of non-infringement in July 2025.
• Acuitas Therapeutics, Inc. filed a declaratory judgment action on July 12, 2024, seeking co-inventorship on patents asserted against Pfizer/BioNTech and Moderna. The District Court granted the company's motion to dismiss the complaint without prejudice on July 1, 2025.
• The Board of Regents of the University of Texas System filed a lawsuit on December 12, 2024, alleging infringement of U.S. Patent No. 8,895,717 by ONPATTRO. Motions to dismiss and transfer the case were denied without prejudice on July 2, 2025, allowing for refiling after venue discovery.

Stakeholder Impact

• Shareholders: Experienced increased net loss and potential stock price volatility due to financial results and adverse legal outcomes. Potential for dilution from convertible notes and impact of Rule 10b5-1 trading plans by officers and directors.
• Patients: Benefit from expanded access to AMVUTTRA for ATTR amyloidosis with cardiomyopathy and Qfitlia for hemophilia. Continued development of pipeline products like zilebesiran, nucresiran, and mivelsiran offers future therapeutic options.
• Employees: Increased compensation costs and stock-based compensation. The company's growth strategy necessitates attracting and retaining qualified personnel, impacting employee opportunities.
• Collaborators: Regeneron's opt-out from mivelsiran co-development shifts funding responsibility. Novartis and Sanofi continue to contribute significant royalty revenue from Leqvio and Qfitlia sales, respectively. The Roche collaboration for zilebesiran is progressing.
• Suppliers/CMOs: Continued reliance on third-party contract manufacturing organizations (CMOs) for product and candidate supply, with inherent risks of supply disruption and regulatory compliance challenges.
• Creditors: Holders of convertible notes face risks related to the company's ability to service its debt and make cash payments upon conversion, potentially impacting liquidity.

Next Steps

• Report results from the KARDIA-3 Phase 2 clinical trial for zilebesiran in the second half of 2025.
• Initiate a Phase 3 cardiovascular outcomes clinical trial for zilebesiran in the second half of 2025.
• Initiate the TRITON-PN Phase 3 clinical trial of nucresiran in patients with hATTR polyneuropathy in late 2025.
• Initiate a Phase 2 clinical trial of mivelsiran in patients with Alzheimer's disease in the second half of 2025.
• Continue to expand global commercial and compliance infrastructure.
• Prepare for future commercial product launches, including the continued launch of AMVUTTRA for ATTR amyloidosis with cardiomyopathy.
• Advance product candidates, including collaborated programs, into later-stage development.
• Advance and develop the RNAi platform and preclinical pipeline.
• Prepare regulatory submissions for product candidates.
• Monitor legislative reforms and assess their potential impact on operations.
• Evaluate the impact of new accounting standards (ASU 2024-04, ASU 2024-03, ASU 2023-09) on consolidated financial statements and disclosures.
• Evaluate the impact of the One Big Beautiful Bill Act (H.R. 1) on future tax periods.
• Consider options for further action regarding the Court of Appeals for the Federal Circuit's ruling in the Moderna lawsuit.
• Evaluate options, including a potential appeal to the Court of Appeals for the Federal Circuit, regarding the Pfizer lawsuit's summary judgment of non-infringement.
• Refile motions to dismiss/transfer the University of Texas lawsuit following the conclusion of venue discovery.

Key Dates

Recommendation

Alnylam Pharmaceuticals demonstrates robust product revenue growth, particularly with AMVUTTRA's expanded indications and strong demand, and increasing royalty income from key collaborations. The pipeline continues to advance with positive clinical data and Fast Track designation for nucresiran. However, the company reported a significantly increased net loss and higher operating expenses, indicating challenges in achieving profitability despite revenue growth. Furthermore, recent adverse outcomes in major patent infringement lawsuits against Moderna and Pfizer, coupled with new litigation from the University of Texas, introduce substantial legal and financial uncertainties. While the commercial momentum is positive, the escalating losses and ongoing legal risks suggest a 'Hold' recommendation, as investors should monitor the company's path to sustainable profitability and the resolution of its intellectual property challenges.

Keywords

RNAi therapeutics, Biopharmaceutical, Rare diseases, ATTR amyloidosis, Cardiomyopathy, Polyneuropathy, Hereditary transthyretin-mediated amyloidosis, AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio, Qfitlia, Hypertension, Zilebesiran, Alzheimer's disease, Cerebral amyloid angiopathy, Mivelsiran, Nucresiran, Hemophilia, Acute hepatic porphyria, Primary hyperoxaluria type 1, Clinical trials, Regulatory approval, Commercialization, Patent litigation, Collaborations, Novartis, Sanofi, Roche, Regeneron, SEC filing, Financial results